title: Elevation of soluble thrombomodulin antigen levels in the serum and urine of streptozotocin-induced diabetes model rats.
abstract: The present study was designed to evaluate the serum thrombomodulin (TM) antigen levels, the TM content in several tissues, and vascular endothelium injury in a streptozotocin-induced diabetic mellitus model of rats with the basic observations concerning soluble serum TM antigen. The soluble TM antigen levels in the serum of 1-week-old Sprague-Dawley rats were 1028.7+/-56.8 ng/mL in the immunoassay using rabbit anti-rat TM IgG. The levels gradually decreased to about 400 ng/mL within 11 weeks during the development, and the levels in 11-week-old rats were preserved up to 31 weeks of age (experimental period). Identical patterns of five kinds of TM antigen subspecies (105, 52, 46, 31, and 28 kDa) in the serum were observed during normal development from 1 to 31 weeks in the Western blotting under reducing conditions. Soluble TM antigen levels in the serum and urine of the model rats were significantly increased to 1. 3 times the levels in the buffer-administrated control rats without an increase in the serum creatinine levels. In contrast to the TM antigen levels in the serum and urine, the TM content in several tissues including the lung, pancreas, kidney, and spleen of the model rats significantly decreased by 47% to 10% of those in the buffer-administrated control rats. Flattening of the longitudinal ridges in the endothelium, crevasse-like endothelial sloughing, platelet activation and aggregation, and/or leukocyte adherence on the endothelium were observed in the aorta of the model rats based on scanning electron microscopic observations, indicating endothelium injury. The present results indicate that the serum TM antigen levels increased with injury to the endothelium in the model, even when renal dysfunction was not present. It is suggested that increased TM antigen levels in diabetic patients could reflect endothelium injury as observed in this diabetic model experiment.
authors.affiliation: Niigata Research Laboratory, Mitsubishi Gas Chemical Company, Inc., Niigata, Japan. masahiko-nakano@mgc.co.jp
authors.forename: M
authors.initials: M
authors.lastname: Nakano
authors.forename: M
authors.initials: M
authors.lastname: Furutani
authors.forename: H
authors.initials: H
authors.lastname: Shinno
authors.forename: T
authors.initials: T
authors.lastname: Ikeda
authors.forename: K
authors.initials: K
authors.lastname: Oida
authors.forename: H
authors.initials: H
authors.lastname: Ishii
mesh_terms: D000818:Animals; D000941:Antigens / Q000097:blood / Q000652:urine; D015153:Blotting, Western; D002448:Cell Adhesion; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced; D004195:Disease Models, Animal; D004730:Endothelium, Vascular / Q000293:injuries / Q000473:pathology / Q000648:ultrastructure; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007074:Immunoglobulin G; D008297:Male; D008855:Microscopy, Electron, Scanning; D015539:Platelet Activation; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D013311:Streptozocin; D018180:Thrombomodulin / Q000276:immunology / Q000378:metabolism*; D013997:Time Factors; D014018:Tissue Distribution
chemical_list: D000941:Antigens; D007074:Immunoglobulin G; D018180:Thrombomodulin; D013311:Streptozocin